San Francisco Bay Area biotech stories.
Friday, June 22, 2012
Depomed buys rights to pain drug Zipsor for $26 million
Depomed Inc. bought the rights to the pain treatment Zipsor from Xanodyne Pharmaceuticals Inc. for $25.9 million in cash
Menlo Park-based Depomed (NASDAQ: DEPO) also agreed to possible milestone payments based on how well the drug (diclofenac potassium) sells. It typically brings in $19 million a year.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)